• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Renovaro Inc.

    2/18/25 4:51:56 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RENB alert in real time by email
    NT 10-Q 1 e6370_nt-10q.htm FORM NT 10-Q

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☐  Form 10-K ☐  Form 20-F ☐  Form 11-K ☒  Form 10-Q ☐  Form 10-D ☐  Form N-CEN ☐  Form N-CSR

     

      For Period Ended: December 31, 2024
         
      ☐ Transition Report on Form 10-K
         
      ☐ Transition Report on Form 20-F
         
      ☐ Transition Report on Form 11-K
         
      ☐ Transition Report on Form 10-Q
         
      For the Transition Period Ended: _________________________________________________ 

     

    Read Instructions (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
     
     
    PART I — REGISTRANT INFORMATION

     

    Renovaro Inc.
    Full Name of Registrant
     
     
    Former Name if Applicable
     
    2080 Century Park East, Suite 906
    Address of Principal Executive Office (Street and Number)
     
    Los Angeles, CA 90067
    City, State and Zip Code

     

     

     

    PART II — RULES 12b-25(b) AND (c)
     
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

     

    Renovaro Inc., a Delaware corporation (the “Company”), is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 (the “Form 10-Q”).

     

    The Company could not complete the filing of its Form 10-Q within the prescribed time period without unreasonable effort or expense because additional time is needed to finalize the financial statements to be included in such report, particularly related to the settled equity and the total outstanding equity as of December 31, 2024.The Registrant anticipates that it will file its Form 10-Q within the five-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification
     
      Nathen Fuentes   (305)   918-1980
      (Name)   (Area Code)   (Telephone Number)
     
    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
    Yes ☒ No    ☐
       
     
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
    Yes ☒ No   ☐ 
     
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

    The following material changes are anticipated to the Company’s balance sheet and statement of operations as of and for the quarter ended December 31, 2024 as compared to the corresponding period for the prior fiscal year:

     

      ● Cash increased from $220,467 at June 30, 2024 to $311,764 at December 31, 2024.
      ● Insurance receivable decreased from $1,108,247 at June 30, 2024 to $127,080 at December 31, 2024.
      ● Goodwill decreased from $159,330,161 at June 30, 2024 to $107,999,273 at December 31, 2024.
      ● Accounts payable - trade increased from $9,448,683 at June 30, 2024 to $10,934,555 at December 31, 2024.
      ● Accrued expenses increased from $5,311,324 at June 30, 2024 to $5,512,004 at December 31, 2024.
      ● Notes payable, net (current) increased from $2,205,996 at June 30, 2024 to $4,885,000 at December 31, 2024.
      ● Contingent consideration liability (current) decreased from $12,310,000 at June 30, 2024 to $5,650,000 at December 31, 2024.
      ● Additional paid in capital increased from $464,587,224 at June 30, 2024 to $469,810,215 at December 31, 2024.
      ● Accumulated deficit increased from $332,455,081 at June 30, 2024 to $383,919,510 at December 31, 2024.
      ● Other comprehensive income (loss) increased from ($170,846) at June 30, 2024 to ($3,847,603) at December 31, 2024.
      ● General and administrative expenses increased from $3,616,392 for the three months ended December 31, 2023 to $4,353,123 for the three months ended December 31, 2024.
      ● General  and administrative expenses decreased from $11,906,602 for the six months ended December 31, 2023 to $9,654,373 for the six months ended December 31 2024.
      ● Research and development expenses decreased from $620,521 for the three months ended December 31, 2023 to $161,084 for the three months ended December 31, 2024.
      ● Research  and development expenses decreased from $1,187,165 for the six months ended December 31, 2023 to $551,273 for the six months ended December 31, 2024.
      ● Goodwill impairment expenses increased from zero for the six months ended December 31, 2023 to $47,614,729 for the six months ended December 31, 2024.
      ● Loss on extinguishment of debt decreased from $(120,018) for the six months December 31, 2023 to zero for the six months ended December 31, 2024.
      ● Change in fair value of contingent consideration increased from zero for the three months ended December 31, 2023 to $($2,590,000) for the three months ended December 31, 2024.
      ● Change in fair value of contingent consideration increased from zero for the six months ended December 31, 2023 to $6,660,000 for the six months ended December 31, 2024.

     

    The amounts reported above are still under review by the Registrant’s independent registered public accounting firm and accounting staff and may differ once reported in the Form 10-Q to be filed by the Registrant.

     

     

     

    Renovaro Inc.
    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

             

    Date: February 18, 2025   By: /s/ Nathen Fuentes
            Nathen Fuentes
    Chief Financial Officer

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

    ATTENTION
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $RENB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RENB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RENB
    SEC Filings

    See more
    • Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/18/25 5:00:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/10/25 4:55:50 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RENOVARO INC. (0001527728) (Filer)

      2/28/25 4:05:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Leadership Updates

    Live Leadership Updates

    See more
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

      2/26/25 1:25:00 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Appoints Nathen Fuentes as Chief Financial Officer

      Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial l

      1/7/25 9:15:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      3/12/25 8:12:50 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:33:34 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:29:46 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

      LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing ("HPC") built on the latest platform to accelerate biomarker discovery and next-generation diagnostics. David Weinstein, CEO of Renovaro, stated, "By utilizing Nebul'

      4/22/25 9:20:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Provides Update to Definitive Agreement with Predictive Oncology

      LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025

      4/4/25 9:40:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RENB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      11/6/24 5:45:52 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      10/24/24 8:57:01 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      6/24/24 7:56:04 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care